Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 212
Filter
1.
Glia ; 70(10): 1950-1970, 2022 10.
Article in English | MEDLINE | ID: mdl-35809238

ABSTRACT

Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune disease characterized by inflammation, demyelination, and neurodegeneration. The ideal MS therapy would both specifically inhibit the underlying autoimmune response and promote repair/regeneration of myelin as well as maintenance of axonal integrity. Currently approved MS therapies consist of non-specific immunosuppressive molecules/antibodies which block activation or CNS homing of autoreactive T cells, but there are no approved therapies for stimulation of remyelination nor maintenance of axonal integrity. In an effort to repurpose an FDA-approved medication for myelin repair, we chose to examine the effectiveness of digoxin, a cardiac glycoside (Na+ /K+ ATPase inhibitor), originally identified as pro-myelinating in an in vitro screen. We found that digoxin regulated multiple genes in oligodendrocyte progenitor cells (OPCs) essential for oligodendrocyte (OL) differentiation in vitro, promoted OL differentiation both in vitro and in vivo in female naïve C57BL/6J (B6) mice, and stimulated recovery of myelinated axons in B6 mice following demyelination in the corpus callosum induced by cuprizone and spinal cord demyelination induced by lysophosphatidylcholine (LPC), respectively. More relevant to treatment of MS, we show that digoxin treatment of mice with established MOG35-55 -induced Th1/Th17-mediated chronic EAE combined with tolerance induced by the i.v. infusion of biodegradable poly(lactide-co-glycolide) nanoparticles coupled with MOG35-55 (PLG-MOG35-55 ) completely ameliorated clinical disease symptoms and stimulated recovery of OL lineage cell numbers. These findings provide critical pre-clinical evidence supporting future clinical trials of myelin-specific tolerance with myelin repair/regeneration drugs, such as digoxin, in MS patients.


Subject(s)
Cardiac Glycosides , Demyelinating Diseases , Multiple Sclerosis , Animals , Cardiac Glycosides/adverse effects , Cell Differentiation , Cuprizone , Demyelinating Diseases/chemically induced , Digoxin/adverse effects , Disease Models, Animal , Drug Repositioning , Female , Mice , Mice, Inbred C57BL , Multiple Sclerosis/drug therapy , Myelin Sheath/physiology , Oligodendroglia/physiology
2.
Int J Mol Sci ; 19(9)2018 Aug 30.
Article in English | MEDLINE | ID: mdl-30200235

ABSTRACT

In 1972 Neal Bricker presented the "trade-off" hypothesis in which he detailed the role of physiological adaptation processes in mediating some of the pathophysiology associated with declines in renal function. In the late 1990's Xie and Askari published seminal studies indicating that the Na⁺/K⁺-ATPase (NKA) was not only an ion pump, but also a signal transducer that interacts with several signaling partners. Since this discovery, numerous studies from multiple laboratories have shown that the NKA is a central player in mediating some of these long-term "trade-offs" of the physiological adaptation processes which Bricker originally proposed in the 1970's. In fact, NKA ligands such as cardiotonic steroids (CTS), have been shown to signal through NKA, and consequently been implicated in mediating both adaptive and maladaptive responses to volume overload such as fibrosis and oxidative stress. In this review we will emphasize the role the NKA plays in this "trade-off" with respect to CTS signaling and its implication in inflammation and fibrosis in target organs including the heart, kidney, and vasculature. As inflammation and fibrosis exhibit key roles in the pathogenesis of a number of clinical disorders such as chronic kidney disease, heart failure, atherosclerosis, obesity, preeclampsia, and aging, this review will also highlight the role of newly discovered NKA signaling partners in mediating some of these conditions.


Subject(s)
Cardiac Glycosides/adverse effects , Sodium-Potassium-Exchanging ATPase/metabolism , Sodium/metabolism , Animals , Cardiac Glycosides/pharmacology , Fibrosis , Humans , Inflammation/chemically induced , Inflammation/metabolism , Signal Transduction/drug effects
3.
J Emerg Med ; 55(4): 507-511, 2018 10.
Article in English | MEDLINE | ID: mdl-29941374

ABSTRACT

BACKGROUND: A variety of plants contain cardiac glycosides. This has resulted in many of them being used to commit suicide. In southeast Asia, Cerebera odollam (pong-pong or suicide tree) is frequently used for suicidal ingestion. Seeds, or kernels, of this plant can cause hyperkalemia, heart block, and death due to the effects of its cardiac glycosides. CASE REPORT: We describe six cases of pong-pong seed ingestion reported to US poison centers. The most common symptoms were vomiting and bradycardia. Three patients survived and three died. All patients who died had heart block, serum digoxin levels > 1.0 ng/mL, and were treated with anti-digoxin immune FAB. Anti-digoxin immune FAB may be ineffective in a large pong-pong seed ingestion. Patients ingesting pong-pong seeds who develop a potassium level > 8.0 meq/L or have a digoxin level > 1.0 ng/mL may be at a higher risk for death. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: The apparent ease of acquiring C. odollam seeds on the Internet makes knowledge of it important, as it can be used as a means to commit suicide. The apparent failure of digoxin immune FAB to treat toxicity from pong-pong is important, as other lifesaving techniques, such as extracorporeal membrane oxygenation, might be needed in severely toxic patients.


Subject(s)
Apocynaceae/adverse effects , Cardiotoxicity/etiology , Suicide, Attempted , Adult , Bradycardia/etiology , Cardiac Glycosides/adverse effects , Female , Humans , Immunoglobulin Fab Fragments/therapeutic use , Male , Poison Control Centers/organization & administration , Poison Control Centers/statistics & numerical data , Seeds/adverse effects , United States , Vomiting/etiology
4.
PLoS One ; 12(6): e0178611, 2017.
Article in English | MEDLINE | ID: mdl-28591151

ABSTRACT

BACKGROUND: Cardiac glycosides (CGs) including digitalis, digoxin and digitoxin are used in the treatment of congestive heart failure and atrial fibrillation. Pre-clinical studies have investigated the anti-neoplastic properties of CGs since 1960s. Epidemiological studies concerning the association between CGs use and cancer risk yielded inconsistent results. We have performed a systematic review and meta-analysis to summarize the effects of CGs on cancer risk and mortality. METHODS: PubMed, Scopus, Cochrane library, Medline and Web of Knowledge were searched for identifying relevant studies. Summary relative risks (RR) and 95% confidence intervals (CI) were calculated using random-effects model. RESULTS: We included 14 case-control studies and 15 cohort studies published between 1976 and 2016 including 13 cancer types. Twenty-four studies reported the association between CGs and cancer risk and six reported the association between CGs and mortality of cancer patients. Using CGs was associated with a higher risk of breast cancer (RR = 1.330, 95% CI: 1.247-1.419). Subgroup analysis showed that using CGs increased the risk of ER+ve breast cancer but not ER-ve. Using CGs wasn't associated with prostate cancer risk (RR = 1.015, 95% CI: 0.868-1.87). However, CGs decreased the risk in long term users and showed a protective role in decreasing the risk of advanced stages. CGs use was associated with increased all-cause mortality (HR = 1.35, 95% CI: 1.248-1.46) but not cancer-specific mortality (HR = 1.075, 95% CI: 0.968-1.194). CONCLUSION: The anti-tumor activity of CGs observed in pre-clinical studies requires high concentrations which can't be normally tolerated in humans. However, the estrogen-like activity of CGs could be responsible for increasing the risk of certain types of tumors.


Subject(s)
Cardiac Glycosides/adverse effects , Neoplasms/mortality , Observational Studies as Topic , Female , Humans , Male , Risk Factors
5.
Am J Epidemiol ; 185(5): 372-384, 2017 03 01.
Article in English | MEDLINE | ID: mdl-28174828

ABSTRACT

Atrial fibrillation (AF) is a common arrhythmia that poses a significant risk of stroke. Cross-sectional and case-control studies have shown evidence of associations between AF and breast or colorectal cancer, but there have been no longitudinal studies in which this has been assessed. We prospectively examined a cohort of 93,676 postmenopausal women enrolled in the Women's Health Initiative from 1994 to 1998 to determine whether there are relationships between baseline AF and the development of invasive breast or colorectal cancer. The prevalence of self-reported physician diagnosis of AF at baseline was 5.1%. Over approximately 15 years of follow-up, the incidence of invasive breast cancer was 5.7%, and the incidence of colorectal cancer was 1.6%. Adjusted hazard ratios and 95% confidence intervals were obtained using Cox proportional hazards models. We found no significant association between AF and incident colorectal cancer, but we did see a 19% excess risk of invasive breast cancer among those with AF (adjusted hazard ratio (HR) = 1.19, 95% confidence interval (CI): 1.03, 1.38). Additional adjustment for baseline use of cardiac glycosides attenuated the association between AF and invasive breast cancer (HR = 1.01, 95% CI: 0.85, 1.20). Cardiac glycoside use was strongly associated with incident invasive breast cancer (HR = 1.68, 95% CI: 1.33, 2.12) independent of AF and other confounders. Mechanisms of the associations among breast cancer, AF, and cardiac glycosides need further investigation.


Subject(s)
Atrial Fibrillation/epidemiology , Breast Neoplasms/epidemiology , Cardiac Glycosides/adverse effects , Colorectal Neoplasms/epidemiology , Aged , Anti-Arrhythmia Agents/administration & dosage , Anti-Arrhythmia Agents/adverse effects , Atrial Fibrillation/drug therapy , Cardiac Glycosides/administration & dosage , Comorbidity , Female , Humans , Incidence , Middle Aged , Proportional Hazards Models , Prospective Studies , Risk Assessment
6.
Int J Cancer ; 140(5): 1035-1041, 2017 Mar 01.
Article in English | MEDLINE | ID: mdl-27861859

ABSTRACT

Cardiac glycosides are phytoestrogens and have been linked to the risk of estrogen sensitive cancers such as uterus cancer. However, the association between use of cardiac glycosides and risk of breast cancer remains unclear. We investigated the association between cardiac glycosides use and the risk of breast cancer by systematically reviewing the published literature and performing meta-analyses. A comprehensive literature search was performed using MEDLINE, EMBASE, Web of Science and SCOPUS to identify all relevant articles published up to November 2015. Risk estimates, and accompanying standard errors, for the association between cardiac glycoside use and breast cancer were extracted from identified studies. Meta-analysis models were used to calculate a combined hazard ratio (HR), and 95% confidence interval (CI), and to investigate heterogeneity between studies. In total, nine studies were identified investigating cardiac glycosides use and risk of developing breast cancer. Overall, there was evidence to suggest an association between cardiac glycosides use and breast cancer risk (HR = 1.34; 95% CI 1.25, 1.44; p < 0.001) with little variation in the association between studies (I2 = 16%, p for heterogeneity = 0.30). Results were little altered when analysis was restricted to studies with high quality scores or cohort studies. Overall, there was a 34% increase in breast risk with use of cardiac glycosides but it is unclear whether this association reflects confounding or is causal. Further observational studies are required to examine this association particularly for estrogen receptor positive breast cancer and to explore the role of potential confounding variables.


Subject(s)
Breast Neoplasms/chemically induced , Cardiac Glycosides/adverse effects , Estrogens , Neoplasms, Hormone-Dependent/chemically induced , Phytoestrogens/adverse effects , Breast Neoplasms/epidemiology , Causality , Cohort Studies , Confidence Intervals , Confounding Factors, Epidemiologic , Female , Humans , Incidence , Models, Biological , Neoplasms, Hormone-Dependent/epidemiology , Observational Studies as Topic , Registries , Risk Factors , Surveys and Questionnaires
7.
Biomed Pharmacother ; 84: 1036-1041, 2016 Dec.
Article in English | MEDLINE | ID: mdl-27780131

ABSTRACT

Cardiac glycosides, the cardiotonic steroids such as digitalis have been in use as heart ailment remedy since ages. They manipulate the renin-angiotensin axis to improve cardiac output. However; their safety and efficacy have come under scrutiny in recent times, as poisoning and accidental mortalities have been observed. In order to better understand and exploit them as cardiac ionotropes, studies are being pursued using different cardiac glycosides such as digitoxin, digoxin, ouabain, oleandrin etc. Several cardiac glycosides as peruvoside have shown promise in cancer control, especially ovary cancer and leukemia. Functional variability of these glycosides has revealed that not all cardiac glycosides are alike. Apart from their specific affinity to sodium-potassium ATPase, their therapeutic dosage and behavior in poly-morbidity conditions needs to be considered. This review presents a concise account of the key findings in recent years with adequate elaboration of the mechanisms. This compilation is expected to contribute towards management of cardiac, cancer, even viral ailments.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Cardiac Glycosides/therapeutic use , Cardiovascular Agents/therapeutic use , Enzyme Inhibitors/therapeutic use , Heart Diseases/drug therapy , Neoplasms/drug therapy , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors , Animals , Antineoplastic Agents, Phytogenic/adverse effects , Cardenolides/metabolism , Cardiac Glycosides/adverse effects , Cardiovascular Agents/adverse effects , Enzyme Inhibitors/adverse effects , Heart Diseases/enzymology , Heart Diseases/physiopathology , Humans , Neoplasms/enzymology , Neoplasms/pathology , Renin-Angiotensin System/drug effects , Saponins/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism
8.
BMC Cancer ; 14: 573, 2014 Aug 08.
Article in English | MEDLINE | ID: mdl-25104329

ABSTRACT

BACKGROUND: Two studies have reported statistically significant associations between the use of cardiac glycosides (CGs) and an increased risk of lung cancer. However, these studies had a number of methodological limitations. Thus, the objective of this study was to assess this association in a large population-based cohort of patients. METHODS: We used the United Kingdom Clinical Practice Research Datalink (CPRD) to identify a cohort of patients, at least 40 years of age, newly-diagnosed with heart failure, or supra-ventricular arrhythmia. A nested case-control analysis was conducted where each incident case of lung cancer identified during follow-up was randomly matched with up to 10 controls. Exposure to CGs was assessed in terms of ever use, cumulative duration of use and cumulative dose. Rate ratios (RRs) with 95% confidence intervals (CIs) were estimated using conditional logistic regression after adjusting for potential confounders. RESULTS: A total of 129,002 patients were included, and followed for a mean (SD) of 4.7 (3.8) years. During follow-up, 1237 patients were newly-diagnosed with lung cancer. Overall, ever use of CGs was not associated with an increased risk of lung cancer when compared to never use (RR = 1.09, 95% CI: 0.94-1.26). In addition, no dose-response relationship was observed in terms of cumulative duration of use and cumulative dose with all RRs around the null value across quartile categories. CONCLUSION: The results of this large population-based study indicate that the use of CGs is not associated with an increased risk of lung cancer.


Subject(s)
Cardiac Glycosides/adverse effects , Heart Diseases/drug therapy , Lung Neoplasms/etiology , Aged , Cardiac Glycosides/administration & dosage , Case-Control Studies , Female , Humans , Logistic Models , Male , Middle Aged , Risk Assessment
10.
Georgian Med News ; (187): 48-51, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21098893

ABSTRACT

The pharmacodynamics and pharmacokinetics of medications, their therapeutic and toxic effects are age dependant. In the treatment of old people polypharmacy is widely used. The most common results of polypharmacy are increased adverse drug reactions, drug-drug interactions. In this study the use of different medications at the Departments of General Medicine and Cardiology (Tbilisi Republic Hospital) was analyzed. The case histories (1995, 2000 and 2005) of 1708 patients were studied. It was found that in 2005 the number of 60 years and older patients has doubled comparably with 1995, but the number of 24-44 years old patients remained almost the same. The complication rate was higher in elderly as compared with younger patients. It was found that in treatment of elderly population hypotensive drugs, diuretics and cardiac glycosides are used excessively. In the case of excess use of antihypertension medications there is a big risk of developing arterial hypotension. In old people it may lead to orthostatic hypotension, in youth - to dizziness. The frequent use of diuretics in old people may be accompanied with dehydration and risk of developing thromb formation. Hyponatraemia, hypokalaemia, hypomagnesemia lead to heart rhythm disturbances and risk of glycoside intoxication. In old people the therapeutical doses of diuretics depend not only on their biological activity, but also on the ability of their absorption from the gastrointestinal tract, on the organism's resistance and in the case of repeated intake on their cumulation quality and extraction.


Subject(s)
Aging , Antihypertensive Agents , Cardiac Glycosides , Diuretics , Adult , Aged , Antihypertensive Agents/adverse effects , Antihypertensive Agents/pharmacokinetics , Antihypertensive Agents/therapeutic use , Cardiac Glycosides/adverse effects , Cardiac Glycosides/pharmacokinetics , Cardiac Glycosides/therapeutic use , Diuretics/adverse effects , Diuretics/pharmacokinetics , Diuretics/therapeutic use , Female , Georgia (Republic)/epidemiology , Humans , Male , Young Adult
11.
Ther Umsch ; 65(10): 585-92, 2008 Oct.
Article in German | MEDLINE | ID: mdl-18821517

ABSTRACT

As a multi-system disease, chronic heart failure requires a complex, multimodal therapy. Achieving maximum guideline adherence in (advanced) chronic heart failure can therefore become a challenge. The important decrease in morbidity and mortality seen lately largely depends on consequent and sometime tedious implementation of guideline targets. The present paper provides a comprehensive overview on medical therapeutic strategies with a particular focus of onset and discontinuation of drugs in patients with chronic systolic dysfunction.


Subject(s)
Cardiotonic Agents/administration & dosage , Heart Failure/drug therapy , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/adverse effects , Angiotensin II Type 1 Receptor Blockers/administration & dosage , Angiotensin II Type 1 Receptor Blockers/adverse effects , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Cardiac Glycosides/administration & dosage , Cardiac Glycosides/adverse effects , Cardiotonic Agents/adverse effects , Chronic Disease , Diuretics/administration & dosage , Diuretics/adverse effects , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Interactions , Drug Therapy, Combination , Humans , Mineralocorticoid Receptor Antagonists/administration & dosage , Mineralocorticoid Receptor Antagonists/adverse effects , Systole/drug effects
12.
J Anal Toxicol ; 30(9): 683-6, 2006.
Article in English | MEDLINE | ID: mdl-17137529

ABSTRACT

A female, aged 43 and a male, aged 66, experienced gastrointestinal and cardiovascular symptoms after a meal including snail stew. Twelve hours after the ingestion, they presented with nausea, vomiting, diarrhea, and cardiovascular symptoms typical of acute toxic digoxin ingestion and were hospitalized. The man's electrocardiogram was altered, and the woman's was normal. Serum digoxin levels, measured on a Roche COBAS Integra 800 with the Roche On-Line Digoxin reagent, were 1.14 and 1.00 nmol/L, respectively. Potassium levels were normal in both patients. The serum digoxin concentration decreased on the second day, and symptoms resolved on the third day with patients fully recovered (i.e., reversion to a normal sinus rhythm). Cardiac-glycoside-like intoxication symptoms follow the ingestion of leaves or flowers of Nerium oleander. The consumed snails were suspected to be responsible for the intoxication. In the homogenized snail tissue, the concentration expressed in digoxin equivalents was 0.282 nmol/g. The presence of oleandrin and oleandrigenin in the snails was confirmed by liquid chromatography-tandem mass spectrometry analysis, which was performed on a ionic-trap Finnigan LXQ instrument using an electrospray ionization interface. High-pressure liquid chromatographic separation was performed on a C18 column with a gradient of methanol/water. An extract of oleander leaves was used as reference.


Subject(s)
Foodborne Diseases/etiology , Snails , Adult , Aged , Animals , Cardenolides/adverse effects , Cardiac Glycosides/adverse effects , Digoxin/blood , Digoxin/urine , Female , Food Chain , Foodborne Diseases/blood , Foodborne Diseases/urine , Humans , Male , Nerium/chemistry
13.
Clin Cardiol ; 29(9): 388-92, 2006 Sep.
Article in English | MEDLINE | ID: mdl-17007169

ABSTRACT

Potassium (K) concentration plays a significant role in cell metabolism and membrane excitability. The imbalance of serum potassium is important because it can lead to life-threatening events. Potassium balance may be lost both through the neurohormonal mechanisms involved in cardiovascular diseases and through the drugs used in the treatment of this illness. Avoiding both hypo- and hyperkalemia is beneficial in several cardiovascular diseases, especially heart failure. Electrolyte abnormalities are frequently seen complications in subjects with heart failure. Malignant ventricular arrhythmias and sudden cardiac death are particularly feared complications in K+ instability.


Subject(s)
Heart Failure/blood , Homeostasis , Potassium/blood , Adenosine Triphosphatases/blood , Adenosine Triphosphatases/drug effects , Angiotensin II Type 1 Receptor Blockers/adverse effects , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Biomarkers/blood , Cardiac Glycosides/adverse effects , Fibrinolytic Agents/adverse effects , Heart Failure/physiopathology , Heparin/adverse effects , Homeostasis/drug effects , Humans , Hyperkalemia/blood , Hyperkalemia/chemically induced , Hypokalemia/blood , Hypokalemia/chemically induced , Randomized Controlled Trials as Topic , Sodium Channel Blockers/adverse effects
14.
Chin Med Sci J ; 21(1): 16-9, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16615278

ABSTRACT

OBJECTIVE: To investigate the effectiveness and safety of various agents on paroxysmal atrial fibrillation in the elderly over 75 years old. METHODS: Totally 264 in-patients (75-91 years old, 185 males and 79 females) with atrial fibrillation history of less than 7 days were enrolled in this study. A total of 611 atrial fibrillation episodes were recorded, but 130 episodes (22.3%) of atrial fibrillation were auto-converted to sinus rhythm. The rest 481 episodes of atrial fibrillation were divided into six groups based on the drug used. RESULTS: The cardioversion ratio of atrial fibrillation were 9.5%, 46.9%, 71.7%, 55.9%, 32.7%, and 73.6% in control, cedilanid, amiodarone, propafenone, verapamil, and quinidine groups, respectively. Ventricular rate control were 5.4%, 83.6%, 84.9%, 77.9%, 78.8%, and 11.3% in those groups, respectively. The total effective rates of amiodarone and cedilanid groups were the highest. When the ventricular rate was controlled to below 90 bpm, the patients would almost complain of no discomfort. No severe side-effect was observed in each group. CONCLUSION: Amiodarone and cedilanid may be the proper drugs for the treatment of paroxysmal atrial fibrillation in the elderly. The above antiarrhythmics in each therapeutic group were relatively safe and effective.


Subject(s)
Amiodarone/therapeutic use , Anti-Arrhythmia Agents/therapeutic use , Atrial Fibrillation/drug therapy , Lanatosides/therapeutic use , Aged , Aged, 80 and over , Amiodarone/adverse effects , Anti-Arrhythmia Agents/adverse effects , Bradycardia/chemically induced , Cardiac Glycosides/adverse effects , Cardiac Glycosides/therapeutic use , Female , Heart Rate/drug effects , Humans , Lanatosides/adverse effects , Male , Nausea/chemically induced , Propafenone/adverse effects , Propafenone/therapeutic use
15.
Cardiol Rev ; 12(4): 201-21, 2004.
Article in English | MEDLINE | ID: mdl-15191632

ABSTRACT

Cardiovascular drugs are often used in pregnancy for the treatment of maternal and fetal conditions. Mothers could also require continued postpartum drug therapy. Most cardiovascular drugs taken by pregnant women can cross the placenta and therefore expose the developing embryo and fetus to their pharmacologic and teratogenic effects. These effects are influenced by the intrinsic pharmacokinetic properties of a given drug as well as by the complex physiological changes occurring during pregnancy. Many drugs are also transferred into human milk and therefore can potentially have adverse effects on the nursing infant. This 2-part article summarizes some of the available literature concerning the risks and benefits of using various cardiovascular drugs and drug classes during pregnancy and lactation. Included in the discussion are cardiac glycosides, antiarrhythmic drugs, drugs used to treat both acute and chronic hypertension, cholesterol-lowering agents, anticoagulants, thrombolytics, and antiplatelet drugs.


Subject(s)
Abnormalities, Drug-Induced/prevention & control , Anti-Arrhythmia Agents/adverse effects , Lactation , Maternal-Fetal Exchange/drug effects , Pregnancy , Prenatal Exposure Delayed Effects , Anti-Arrhythmia Agents/pharmacokinetics , Anti-Arrhythmia Agents/therapeutic use , Breast Feeding/adverse effects , Cardiac Glycosides/adverse effects , Cardiac Glycosides/pharmacokinetics , Cardiac Glycosides/therapeutic use , Cardiovascular System/drug effects , Female , Fetus/blood supply , Humans , Infant
16.
Med Klin (Munich) ; 96(8): 442-50, 2001 Aug 15.
Article in German | MEDLINE | ID: mdl-11560044

ABSTRACT

OBJECTIVES: Cardiovascular drugs are the most often prescribed drug class in Germany. The objective of this study is to analyze the adverse drug reaction (ADR) profiles of these drugs and to identify some targets for prevention of ADR. METHOD: Since 1997 specially trained medical staff members of five Pharmacovigilance Centers in Germany prospectively screened all hospital admissions at the departments of internal medicine of five large teaching hospitals. ADR leading to hospital admission were registered and reported. Especially ADR caused by cardiovascular drugs and all factors, which could have been important for their occurrence were analyzed. RESULTS: 559 of 2270 (24.6%) registered ADR cases were related to cardiovascular drugs. The drugs most frequently related to ADR were angiotensin inhibitors (17.9%), digitalis (17.3%), calcium channel blockers (13.9%), beta blockers (12.8%), and diuretics (12.2%). The most often observed ADR were arrhythmias (27.1%), syncopes and blood pressure dysregulations (25.1%), gastrointestinal symptoms (12.4%), and metabolic disorders (10.2%). 72% of patients were older than 65 years. Older patients were on a significantly higher number of drugs (6.2 +/- 2.4 vs 5.5 +/- 3.2; p < 0.001) than the younger ones. Furthermore, they were hospitalized significantly longer (13.2 +/- 9.9 vs 15.3 +/- 9.3 days; p < 0.01). Eleven patients (2%) died because of ADR due to cardiovascular drugs. CONCLUSIONS: Cardiovascular drugs are frequently used. They are prescribed mainly to older patients. Often observed ADR can be prevented effectively by considering their indication, by a clear definition of the therapeutic target, by a dose adjustment to the individual clinical parameters of the patient and by regular control investigations. The large number of drug-induced rhythm disorders--in particular bradycardia--show that extraordinary attention should be paid to rhythm-affecting drugs. The detailed instruction of the patient about therapeutic aims, risks and a concrete guideline for the therapy/drug handling is generally necessary.


Subject(s)
Arrhythmias, Cardiac/chemically induced , Arrhythmias, Cardiac/prevention & control , Cardiovascular Agents/adverse effects , Adrenergic beta-Antagonists/adverse effects , Adverse Drug Reaction Reporting Systems , Aged , Aged, 80 and over , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/mortality , Calcium Channel Blockers/adverse effects , Cardiac Glycosides/adverse effects , Cardiovascular Agents/pharmacokinetics , Diuretics/adverse effects , Drug Interactions , Female , Germany/epidemiology , Humans , Incidence , Male , Retrospective Studies , Syncope/chemically induced
17.
Clin Chem ; 44(5): 1096-109, 1998 May.
Article in English | MEDLINE | ID: mdl-9590394

ABSTRACT

In this Standard of Laboratory Practice we recommend guidelines for therapeutic monitoring of cardiac drugs. Cardiac drugs are primarily used for treatment of angina, arrhythmias, and congestive heart failure. Digoxin, used in congestive heart failure, is widely prescribed and therapeutically monitored. Monitoring and use of antiarrhythmics such as disopyramide and lidocaine have been steadily declining. Immunoassay techniques are currently the most popular methods for measuring cardiac drugs. Several reasons make measurement of cardiac drugs in serum important: their narrow therapeutic index, similarity in clinical complications and presentation of under- and overmedicated patients, need for dosage adjustments, and confirmation of patient compliance. Monitoring may also be necessary in other circumstances, such as assessment of acetylator phenotypes. We present recommendations for measuring digoxin, quinidine, procainamide (and N-acetylprocainamide), lidocaine, and flecainide. We discuss guidelines for measuring unbound digoxin in the presence of an antidote (Fab fragments), for characterizing the impact of digoxin-like immunoreactive factor (DLIF) and other cross-reactants on immunoassays, and for moni-toring the unbound (free fraction) of drugs that bind to alpha1-acid glycoprotein. We also discuss logistic, clinical, hospital, and laboratory practice guidelines needed for implementation of a successful therapeutic drug monitoring service for cardiac drugs.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors/blood , Anti-Arrhythmia Agents/blood , Calcium Channel Blockers/blood , Cardiac Glycosides/blood , Drug Monitoring/standards , Vasodilator Agents/blood , Angina Pectoris/blood , Angina Pectoris/drug therapy , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Angiotensin-Converting Enzyme Inhibitors/pharmacokinetics , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Anti-Arrhythmia Agents/adverse effects , Anti-Arrhythmia Agents/pharmacokinetics , Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/blood , Arrhythmias, Cardiac/drug therapy , Blood Specimen Collection/standards , Calcium Channel Blockers/adverse effects , Calcium Channel Blockers/pharmacokinetics , Calcium Channel Blockers/therapeutic use , Cardiac Glycosides/adverse effects , Cardiac Glycosides/pharmacokinetics , Cardiac Glycosides/therapeutic use , Drug Interactions , Heart Failure/blood , Heart Failure/drug therapy , Humans , Immunoassay/standards , Vasodilator Agents/adverse effects , Vasodilator Agents/pharmacokinetics , Vasodilator Agents/therapeutic use
19.
Toxicology ; 109(1): 1-13, 1996 May 03.
Article in English | MEDLINE | ID: mdl-8619248

ABSTRACT

The oleander is an attractive and hardy shrub that thrives in tropical and subtropical regions. The common pink oleander, Nerium oleander, and the yellow oleander, Thevetia peruviana, are the principle oleander representatives of the family Apocynaceae. Oleanders contain within their tissues cardenolides that are capable of exerting positive inotropic effects on the hearts of animals and humans. The cardiotonic properties of oleanders have been exploited therapeutically and as an instrument of suicide since antiquity. The basis for the physiological action of the oleander cardenolides is similar to that of the classic digitalis glycosides, i.e. inhibition of plasmalemma Na+,K+ ATPase. Differences in toxicity and extracardiac effects exist between the oleander and digitalis cardenolides, however. Toxic exposures of humans and wildlife to oleander cardenolides occur with regularity throughout geographic regions where these plants grow. The human mortality associated with oleander ingestion is generally very low, even in cases of intentional consumption (suicide attempts). Experimental animal models have been successfully utilized to evaluate various treatment protocols designed to manage toxic oleander exposures. The data reviewed here indicate that small children and domestic livestock are at increased risk of oleander poisoning. Both experimental and established therapeutic measures involved in detoxification are discussed.


Subject(s)
Cardenolides/adverse effects , Cardiac Glycosides/adverse effects , Cardiotonic Agents/adverse effects , Plant Poisoning/etiology , Plants, Toxic , Animals , Cardenolides/toxicity , Cardiac Glycosides/toxicity , Cardiotonic Agents/toxicity , Humans , Plant Extracts/adverse effects , Plant Extracts/toxicity , Plant Poisoning/epidemiology , Plant Poisoning/therapy , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors , Suicide, Attempted
SELECTION OF CITATIONS
SEARCH DETAIL
...